Sulfonylureas: Assets in the past, present and future

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 3, 2015, Pages 314-316

  Kalra, Sanjay ^a   Madhu, S V ^b   Bajaj, Sarita ^c  

^a India   (India)

^b UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^c MLN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84981240549     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.149925     Document Type: Review

References (25)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96.
2. Gerich JE. Sulfonylureas in the treatment of diabetes mellitus-1985. Mayo Clin Proc 1985;60:439-43.
3. AACE. Comprehensive Diabetes Management Algoritm; 2013. Available from: https://www.aace.com/files/aace-algorithm.pdf. [Last accessed on 2014 Dec 01].
4. Translation from Evidence-based Practice Guideline for the Treatment of Diabetes in Japan (2012-2013). Available from: http://www.jds. or.jp/e/index.html. [Last accessed on 2014 Dec 1].
5. Chinese guideline for the management of type 2 diabetes mellitus (2013 edition). Chin J Diabetes Mellitus 2014;6:447-98. [In Chinese].
6. Korean diabetes association treatment guideline for diabetes. J Korean Diabetes Assoc 2011;12:71.
7. Clinical Caring Guideline for Diabetes 2012. Taipei: Chinese Taipei Diabetes Association; 2012.
8. Global Guideline for Type 2 Diabetes. Available from: http://www. idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf. [Last accessed on 2014 Dec 01].
9. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011 3;154:602-13.
10. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000;14:201-6.
11. Kabadi MU, Kabadi UM. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin Ther 2004;26:63-9.
12. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006;53:87-94.
13. Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol 2014;13:15.
14. Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract 2010;64:1796-801.
15. Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. Effect of exenatide, sitagliptin, or glimepiride on cell secretory capacity in early type 2 diabetes. Diabetes Care 2014;37:2451-8.
16. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43.
17. Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: A Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014;2:E162-75.
18. Zoungas S, Chalmers J, Kengne AP, Pillai A, Billot L, de Galan B, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract 2010;89:126-33.
19. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-10.
20. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9.
21. van Dieren S, Czernichow S, Chalmers J, Kengne AP, de Galan BE, Poulter N, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14:464-9.
22. Kalra S, Bajaj S, Mithal A. Endocrinology and the essential list. Indian J Endocrinol Metab 2012;16:S133-5.
23. Naidoo P, Rambiritch V, Butkow N, Saman S. Optimal utilisation of sulphonylureas in resource-constrained settings. Cardiovasc J Afr 2014;25:83-5.
24. Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, et al. Beyond metformin: Safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: Reflections from a diabetes care editors' expert forum. Diabetes Care 2014;37:2647-59.
25. Kalra S, Gupta Y. Sulfonylureas. J Pak Med Assoc 2015; 65: 101-104.